HomeCompareBIOGF vs NOBL

BIOGF vs NOBL: Dividend Comparison 2026

BIOGF yields 303.03% · NOBL yields 2.14%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BIOGF wins by $1619.97M in total portfolio value
10 years
BIOGF
BIOGF
● Live price
303.03%
Share price
$0.66
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1619.99M
Annual income
$982,313,976.38
Full BIOGF calculator →
NOBL
NOBL
● Live price
2.14%
Share price
$106.01
Annual div
$2.27
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$22.8K
Annual income
$246.19
Full NOBL calculator →

Portfolio growth — BIOGF vs NOBL

📍 BIOGF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBIOGFNOBL
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BIOGF + NOBL cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BIOGF pays
NOBL pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BIOGF
Annual income on $10K today (after 15% tax)
$25,757.58/yr
After 10yr DRIP, annual income (after tax)
$834,966,879.92/yr
NOBL
Annual income on $10K today (after 15% tax)
$182.19/yr
After 10yr DRIP, annual income (after tax)
$209.26/yr
At 15% tax rate, BIOGF beats the other by $834,966,670.66/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BIOGF + NOBL for your $10,000?

BIOGF: 50%NOBL: 50%
100% NOBL50/50100% BIOGF
Portfolio after 10yr
$810.01M
Annual income
$491,157,111.28/yr
Blended yield
60.64%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BIOGF buys
0
NOBL buys
0
No recent congressional trades found for BIOGF or NOBL in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBIOGFNOBL
Forward yield303.03%2.14%
Annual dividend / share$2.00$2.27
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$1619.99M$22.8K
Annual income after 10y$982,313,976.38$246.19
Total dividends collected$1556.25M$2.3K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: BIOGF vs NOBL ($10,000, DRIP)

YearBIOGF PortfolioBIOGF Income/yrNOBL PortfolioNOBL Income/yrGap
1← crossover$41,003$30,303.03$10,914$214.34+$30.1KBIOGF
2$159,996$116,123.00$11,897$218.63+$148.1KBIOGF
3$594,671$423,475.49$12,952$222.72+$581.7KBIOGF
4$2,107,296$1,470,997.14$14,086$226.62+$2.09MBIOGF
5$7,126,460$4,871,653.73$15,302$230.33+$7.11MBIOGF
6$23,022,487$15,397,174.28$16,607$233.85+$23.01MBIOGF
7$71,121,500$46,487,438.99$18,007$237.18+$71.10MBIOGF
8$210,314,839$134,214,834.84$19,508$240.35+$210.30MBIOGF
9$595,961,579$370,924,701.05$21,116$243.35+$595.94MBIOGF
10$1,619,992,866$982,313,976.38$22,841$246.19+$1619.97MBIOGF

BIOGF vs NOBL: Complete Analysis 2026

BIOGFStock

Biocartis Group NV, a molecular diagnostics company, provides diagnostic solutions enhancing clinical practice for the benefit of patients, clinicians, payers, and healthcare industry with a focus on oncology. Its proprietary molecular diagnostics Idylla platform is a real-time polymerase chain reaction system that offers molecular information that allows treatment selection and treatment progress monitoring. The company offers Idylla BRAF, KRAS, MSI, EGFR, and NRAS-BRAF mutation tests; and Idylla SARS-CoV-2/Flu/RSV panels and SARS-CoV-2 tests, as well as SeptiCyte RAPID, a rapid host-response test. It also provides research products, including MSI, KRAS, BRAF, ctEGFR, NRAS-BRAF-EGFR S492R, ctKRAS, EGFR, GeneFusion, ctBRAF, and ctNRAS-BRAF-EGFR S492R mutation assays. The company has a collaboration agreement with Amgen to evaluate Idylla RAS testing as a tool for rapid decentralized testing and/or to accelerate access to RAS biomarker information using Idylla platform and RAS tests; and Bristol-Myers Squibb Company for the registration of diagnostic and use of the Idylla MSI test in connection with immuno-oncology therapies. It also has a license, development, and commercialization agreement with GeneproDx for the development of ThyroidPrint novel genomic test on the Idylla platform. The company was founded in 2007 and is headquartered in Mechelen, Belgium.

Full BIOGF Calculator →

NOBLETF

The fund will invest at least 80% of its total assets in component securities of the index. The index contains a minimum of 40 stocks, which are equally weighted, and no single sector is allowed to comprise more than 30% of the index weight. It seeks to remain fully invested at all times in securities and/or financial instruments that, in combination, provide exposure to the returns of the index without regard to market conditions, trends or direction.

Full NOBL Calculator →
📬

Get this BIOGF vs NOBL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BIOGF vs SCHDBIOGF vs JEPIBIOGF vs OBIOGF vs KOBIOGF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.